What's in Mineralys Therapeutics Inc.'s pipeline?

Mineralys Therapeutics Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Mineralys Therapeutics Inc.'s portfolio?

Top competitors by shared drug class: Creabilis SA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mineralys-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Mineralys Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mineralys Therapeutics Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
lorundrostat Dose 1	lorundrostat Dose 1	phase 3	11β-HSD1 inhibitor	11β-HSD1	Metabolic disorders

Therapeutic area mix

Metabolic disorders · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Creabilis SA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mineralys Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Mineralys Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mineralys-therapeutics-inc. Accessed 2026-05-16.